Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay-Results From the SAFIA Phase III Trial.

Khalid Alsaleh,Heba Al Zahwahry,Adda Bounedjar,Mohammed Oukkal,Ahmed Saadeddine,Hassen Mahfouf,K. Bouzid,Assia Bensalem,Taha Filali,Hikmat Abdel-Razeq,Blaha Larbaoui,Alaa Kandil,Omalkhair Abulkhair,Meteb Al-Foheidi,Hassan Errihani,Marwan Ghosn,N Abdel-Aziz,Maria Arafah,Hamouda Boussen,F. Dabouz,Haleem Rasool,Mohun R.K. Bahadoor,Jihen Ayari,S Kullab,Jean-Marc Nabholtz

Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay-Results From the SAFIA Phase III Trial.

2021

PURPOSELuminal, human epidermal growth factor receptor 2–negative breast cancer represents the most common subtype of breast malignancies. Neoadjuvant strategies of operable breast cancer are mostl...

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations